FDA notifications. FDA approves pediatric efficacy supplement for didanosine capsules.
D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D016049:Didanosine / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D017277:Drug Approval / Q000331:legislation & jurisprudence*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D010372:Pediatrics; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D014481:United States; D014486:United States Food and Drug Administration
D018894:Reverse Transcriptase Inhibitors; D016049:Didanosine